<DOC>
	<DOCNO>NCT00513175</DOCNO>
	<brief_summary>The primary objective study examine transplant relate mortality ( TRM ) 100 day &lt; 30 % . A TRM &gt; 50 % consider unacceptable . This study also seek TRM 12 month &lt; 50 % , engraftment &gt; 90 % ( define donor cell &gt; 80 % 6 month ) , 1 year overall survival &gt; 50 % .</brief_summary>
	<brief_title>Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors Treatment Hematologic Malignancies , Renal Cell Carcinoma , Aplastic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>&lt; 75 year old Availability suitable match unrelated donor . We require HLA match 9 10 locus include HLA A , B , C , DR DQ . For patient treated UCSF , type do UCSF Immunogenetics Department . Typing do highresolution technique allele level . Donors recruit National Marrow Donor Program ( NMDP ) . Donors must meet standard NMDP well Institutional standard donor center collect . Disease must stable respond therapy . The expected time disease progression great 12 week . Disease type include : Acute myeloid leukemia expect curable chemotherapy . This include patient highrisk cytogenetics ( 7 , 7q , 5 , 5q , complex , Ph+ ) , evolution prior myelodysplasia AML secondary prior chemotherapy , failure achieve remission , second subsequent remission . To ensure adequate time disease progression , marrow blast must &lt; 10 % . This may achieve use chemotherapy treatment . Myelodysplasia highrisk feature . These include adverse cytogenetics ( 7 , 7q , 5 , 5q , complex ) , excess blast , prior conversion AML , severe cytopenia , ANC &lt; 500uL platelet &lt; 20,000uL . Marrow blast must &lt; 10 % . This may achieve use chemotherapy . Acute lymphoblastic leukemia expect curable chemotherapy . This include patient highrisk cytogenetics ( Ph+ , 11q23 abnormality , monosomy 7 ) , patient require one induction course achieve remission , well patient fail enter remission second subsequent remission . Marrow blast must &lt; 10 % . Chronic lymphocytic leukemia highrisk feature . This include refractoriness initial subsequent therapy , progression initial response therapy , prolymphocytic ( PLL ) morphology . Follicular lymphoma highrisk feature . This include refractoriness initial subsequent therapy , progression response initial therapy , &gt; equal 3 IPI risk factor . Multiple myeloma , stage IIIII . Patients eligible either diagnosis initial progression . Other lymphomas include diffuse large cell lymphoma , mantle cell lymphoma , Hodgkin 's disease fail respond primary therapy , progress recur prior therapy . Myeloproliferative disease ( myelofibrosis , polycythemia vera essential thrombocytosis ) evidence disease acceleration . Chronic myeloid leukemia failure disease control Imatinib . Renal cell carcinoma metastatic disease Aplastic anemia responsive immunosuppressive therapy Laboratory requirement ( within 2 week entry , EF DLCO within 4 week ) : Creatinine ,2.0mg/dL creatinine clearance &gt; 40 mL/min Bilirubin &lt; 3mg/dL , AST &lt; 4x upper limit normal . Patients elevate total bilirubin suspect Gilbert 's Disease eligible direct bilirubin normal . Patients hepatitis C hepatitis B eligible bilirubin AST meet criterion Cardiac ejection fraction &gt; 30 % DLCO &gt; 40 % predict Negative pregnancy test ( female reproductive age ) Absence uncontrolled active infection . Prior stem cell ( bone marrow ) transplantation permit Signed inform consent Active infection require ongoing antibiotic treatment Poor performance status Rapid progression malignant disease Opinion BMT Committee autologous transplant would preferable form treatment Organ function requirement Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Allogeneic SCT</keyword>
	<keyword>Matched unrelated donor</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>aplastic anemia</keyword>
</DOC>